Cargando…

Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review

Background Clostridioides difficile infection (CDI) recurrence is a public health concern as well as a health economic burden. Bezlotoxumab treatment is one way to prevent recurrence; however, its clinical results have not been reported in Japan. Therefore, we investigated the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Nobuaki, Hirai, Jun, Asai, Nobuhiro, Mikamo, Hiroshige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469635/ https://www.ncbi.nlm.nih.gov/pubmed/37664309 http://dx.doi.org/10.7759/cureus.42779

Ejemplares similares

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
por: Mori, Nobuaki, et al.
Publicado: (2023)

Bezlotoxumab in Patients with a Primary Clostridioides difficile Infection: A Literature Review
por: Granata, Guido, et al.
Publicado: (2022)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
por: Mileto, Steven J., et al.
Publicado: (2022)

Fecal Microbiota Transplantation for Fulminant Clostridioides Difficile Infection: A Combined Medical and Surgical Case Series
por: Spartz, Ellen J, et al.
Publicado: (2023)

Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection
por: Mohammad, Al Wahadneh, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Necrotizing pneumonia due to Pseudomonas aeruginosa secondary to severe COVID‐19 pneumonia
por: Hirai, Jun, et al.
Publicado: (2023)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Investigating the Correlation Between Clostridioides difficile Infection and Vitamin D Deficiency
por: Khrais, Ayham, et al.
Publicado: (2023)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation
por: Hagihara, Mao, et al.
Publicado: (2021)

Silver-colored colonies of Staphylococcus argenteus
por: Hirai, Jun, et al.
Publicado: (2023)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

Intra-Abdominal Abscess and Bacteremia Due to Stenotrophomonas maltophilia After Total Gastrectomy: A Case Report and Literature Review
por: Hirai, Jun, et al.
Publicado: (2023)

Clostridioides difficile Infection in the Neurorehabilitation Setting: Importance of a Multidisciplinary Approach and Impact of the Fecal Microbiota Transplantation
por: Secondo, Daniela, et al.
Publicado: (2023)

The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021
por: Hyte, Melanie L., et al.
Publicado: (2022)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer
por: Cornely, Oliver A, et al.
Publicado: (2020)

A Case of Severe Pneumocystis Pneumonia in an HIV-Negative Patient Successfully Treated with Oral Atovaquone
por: Hirai, Jun, et al.
Publicado: (2023)

474. Real-World Experience of the Comparative Effectiveness and Safety of Remdesivir and Combination Therapy (Remdesivir and Monoclonal Antibodies) in Immunosuppressed Patients with Mild to Moderate COVID-19: A Retrospective Single-center Study in a Community Setting
por: Hirai, Jun, et al.
Publicado: (2023)

Factors Associated With Fecal Microbiota Transplant Failure in the Treatment of Recurrent Clostridioides difficile Infection: A Single-Center Retrospective Study
por: Warraich, Fatima, et al.
Publicado: (2023)

Comparison of clinical severity, genotype and toxin gene expression of binary toxin-producing Clostridioides difficile clinical isolates in Japan
por: Matsumoto, Asami, et al.
Publicado: (2022)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
por: Thandavaram, Abhay, et al.
Publicado: (2022)

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
por: Hirai, Jun, et al.
Publicado: (2023)

A Retrospective Study to Compare the Incidence of Hyponatremia after Administration between Linezolid and Tedizolid
por: Shibata, Yuichi, et al.
Publicado: (2023)

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)
por: Sferra, Thomas J, et al.
Publicado: (2023)

Complicated pyelonephritis caused by Proteus alimentorum in a woman with peritoneal cancer: a case report
por: Mori, Nobuaki, et al.
Publicado: (2023)

Atypical Presentation of C. Difficile Infection: Report of a Case with Literature Review
por: Khan, Salman A, et al.
Publicado: (2016)

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient
por: Fein, Aaron, et al.
Publicado: (2022)

Clostridium difficile Infection in Liver Cirrhosis Carries a Higher Risk of Mortality: A Comprehensive Literature Review
por: Meyyur Aravamudan, Veeraraghavan, et al.
Publicado: (2019)

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
por: Shen, Judong, et al.
Publicado: (2020)

Molecular epidemiological analyses of Clostridioides difficile isolates in a university hospital in Japan
por: Ito, Yukitaka, et al.
Publicado: (2023)

Laparoscopic Cholecystectomy During Pregnancy: A Case Report and Review of Literature in Japan
por: Iwai, Takuma, et al.
Publicado: (2020)

COVID-19 disease severity is linked to host immunity as well as lung and gut dysbiosis: a narrative review
por: Asai, Nobuhiro, et al.
Publicado: (2021)

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
por: Asai, Nobuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f7vgigcsg6rtsfu8pg6q6osjti